F Qiu1, W-G Gu, C Li, S-L Nie, F Yu. 1. Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, P.R. China. c13970007228@126.com.
Abstract
OBJECTIVE: This paper aims to investigate the expression level and diagnostic value of miR-19 miR-21 in peripheral blood of patients with undifferentiated lung cancer. PATIENTS AND METHODS: 58 patients with undifferentiated lung cancer hospitalized in the oncology department of The First Affiliated Hospital of Nanchang University from September 2014 to May 2017 were selected as the experimental group, and 42 healthy volunteers in the same period as the control group at the same time. General clinical data in the two groups were collected. The expression levels of miR-19 and miR-21 in peripheral blood of the two groups were measured by Real-Time fluorescence quantitative Polymerase Chain Reaction. The expression levels of peripheral blood miR-19 and miR-21 in large and small cell lung cancer of undifferentiated lung cancer were analyzed and compared. ROC curve was used to analyze the diagnostic value of miR-19 and miR-21 in undifferentiated lung cancer. RESULTS: The expression levels of miR-19 and miR-21 in peripheral blood of the experimental group were significantly higher than those of the control group (p<0.05). The AUC of miR-19 in the diagnosis of undifferentiated lung cancer was 0.854; the sensitivity was 98.30%; the specificity was 54.29% and the cut off was 3.54. The AUC of miR-21 in the diagnosis of undifferentiated lung cancer was 0.923; the sensitivity was 86.20%; the specificity was 76.19% and the cut off was 3.89. The AUC of combined detection in the diagnosis of undifferentiated lung cancer was 0.952; the sensitivity was 86.60%; the specificity was 97.62% and the cut off was 0.68. The specificity of combined detection was higher than that of miR-19 and miR-21 (p<0.05). CONCLUSIONS: MiR-19 and miR-21 are highly expressed in peripheral blood of patients with undifferentiated lung cancer; miR-19 and miR-21 are expected to be used as diagnostic markers for undifferentiated lung cancer.
OBJECTIVE: This paper aims to investigate the expression level and diagnostic value of miR-19miR-21 in peripheral blood of patients with undifferentiated lung cancer. PATIENTS AND METHODS: 58 patients with undifferentiated lung cancer hospitalized in the oncology department of The First Affiliated Hospital of Nanchang University from September 2014 to May 2017 were selected as the experimental group, and 42 healthy volunteers in the same period as the control group at the same time. General clinical data in the two groups were collected. The expression levels of miR-19 and miR-21 in peripheral blood of the two groups were measured by Real-Time fluorescence quantitative Polymerase Chain Reaction. The expression levels of peripheral blood miR-19 and miR-21 in large and small cell lung cancer of undifferentiated lung cancer were analyzed and compared. ROC curve was used to analyze the diagnostic value of miR-19 and miR-21 in undifferentiated lung cancer. RESULTS: The expression levels of miR-19 and miR-21 in peripheral blood of the experimental group were significantly higher than those of the control group (p<0.05). The AUC of miR-19 in the diagnosis of undifferentiated lung cancer was 0.854; the sensitivity was 98.30%; the specificity was 54.29% and the cut off was 3.54. The AUC of miR-21 in the diagnosis of undifferentiated lung cancer was 0.923; the sensitivity was 86.20%; the specificity was 76.19% and the cut off was 3.89. The AUC of combined detection in the diagnosis of undifferentiated lung cancer was 0.952; the sensitivity was 86.60%; the specificity was 97.62% and the cut off was 0.68. The specificity of combined detection was higher than that of miR-19 and miR-21 (p<0.05). CONCLUSIONS:MiR-19 and miR-21 are highly expressed in peripheral blood of patients with undifferentiated lung cancer; miR-19 and miR-21 are expected to be used as diagnostic markers for undifferentiated lung cancer.
Authors: Jody Vykoukal; Johannes F Fahrmann; Nikul Patel; Masayoshi Shimizu; Edwin J Ostrin; Jennifer B Dennison; Cristina Ivan; Gary E Goodman; Mark D Thornquist; Matt J Barnett; Ziding Feng; George A Calin; Samir M Hanash Journal: Cancers (Basel) Date: 2022-08-30 Impact factor: 6.575